mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Bailey, Sean T ^a,b   Zhou, Bing ^a   Damrauer, Jeffrey S ^a,b   Krishnan, Bhavani ^a   Wilson, Harper L ^a   Smith, Aleisha M ^a   Li, Mingqing ^a   Yeh, Jen Jen ^a,b   Kim, William Y ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACTOLISIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; RAPAMYCIN; TRAMETINIB; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

ALLOSTERISM; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; MOLECULAR INTERACTION; MONOTHERAPY; PHARMACOLOGICAL BLOCKING; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOCATALYSIS; DRUG EFFECTS; ENZYMOLOGY; KIDNEY TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ALLOSTERIC REGULATION; ANIMALS; APOPTOSIS; BIOCATALYSIS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR TARGETED THERAPY; MULTIPROTEIN COMPLEXES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84907468719     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104413     Document Type: Article

References (46)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30. doi:10.3322/caac.21166.
2. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, et al. (2012) State of the Science: An Update on Renal Cell Carcinoma. Molecular Cancer Research. doi:10.1158/1541-7786.MCR-12-0117.
3. Conti A, Santoni M, Amantini C, Burattini L, Berardi R, et al. (2013) Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma. BioMed Research International 2013: 1-9. doi:10.1158/0008-5472.CAN-07-5723.
4. Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991-5004. doi:10.1200/JCO.2004.05.061. (Pubitemid 46646218)
5. Hanna SC, Heathcote SA, Kim WY (2008) mTOR pathway in renal cell carcinoma. Expert Rev Anticancer Ther 8: 283-292. doi:10.1586/14737140.8.2.283. (Pubitemid 351385918)
6. Kaelin WG (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873. doi:10.1038/nrc2502.
7. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246. (Pubitemid 41039148)
8. Kondo K, Kim WY, Lechpammer M, Kaelin WG (2003) Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1: E83. doi:10.1371/journal.pbio.0000083.
9. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O (2004) Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2: 89-95. (Pubitemid 38250425)
10. Kim WY, Kaelin WG (2006) Molecular pathways in renal cell carcinoma-rationale for targeted treatment. Semin Oncol 33: 588-595. doi:10.1053/j.seminoncol.2006.06.001. (Pubitemid 44511973)
11. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456. doi:10.1016/S0140-6736(08)61039-9.
12. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281. doi:10.1056/NEJMoa066838. (Pubitemid 46849157)
13. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, et al. (2014) mTOR kinase structure, mechanismand regulation. Nature 497: 217-223. doi:10.1038/nature12122.
14. Guertin DA, Sabatini DM (2007) Defining the Role of mTOR in Cancer. Cancer Cell 12: 9-22. doi:10.1016/j.ccr.2007.05.008. (Pubitemid 47001784)
15. Laplante M, Sabatini DM (2012) mTOR Signaling in Growth Control and Disease. Cell 149: 274-293. doi:10.1016/j.cell.2012.03.017.
16. Sarbassov DD, Ali SM, Kim D-H, Guertin DA, Latek RR, et al. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302. doi:10.1016/j.cub.2004.06.054. (Pubitemid 38991819)
17. O'Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508. doi:10.1158/0008-5472.CAN-05-2925. (Pubitemid 43259931)
18. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, et al. (2000) A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 14: 783-794. (Pubitemid 32260492)
19. Guertin DA, Sabatini DM (2009) The Pharmacology of mTOR Inhibition. Sci Signal 2: pe24. doi:10.1126/scisignal.267pe24.
20. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3Kdependent feedback loop in human cancer. J Clin Invest. doi:10.1172/JCI34739DS1.
21. Wang X, Wang X, Hawk N, Hawk N, Yue P, et al. (2008) Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther 7: 1952-1958. doi:10.4161/cbt.7.12.6944.
22. Zhong H, Sanchez C, Spitrzer D, Plambeck-Suess S, Gibbs J, et al. (2013) Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models. PLoS ONE 8: e77243. doi:10.1371/journal. pone.0077243.
23. Hoang B, Hoang B, Benavides A, Benavides A, Shi Y, et al. (2012) The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance. J Biol Chem 287: 21796-21805. doi:10.1074/jbc.M111.304626.
24. Kinross KM, Kinross KM, Brown DV, Brown DV, Kleinschmidt M, et al. (2011) In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer. Molecular Cancer Therapeutics 10: 1440-1449. doi:10.1158/1535-7163.MCT-11-0240.
25. Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, et al. (2013) Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer 49: 3936-3944. doi:10.1016/j.ejca.2013.08.007.
26. Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, et al. (2012) Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models. Clinical Cancer Research 18: 5290-5303. doi:10.1158/1078-0432.CCR-12-0563.
27. Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E (2013) Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells. PLoS ONE 8: e57289. doi:10.1371/journal.pone.0057289.s001.
28. Renshaw J, Renshaw J, Taylor KR, Taylor KR, Bishop R, et al. (2013) Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin Cancer Res 19: 5940-5951. doi:10.1158/1078-0432.CCR-13-0850.
29. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, et al. (2012) The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18: 2316-2325. doi:10.1158/1078-0432.CCR-11-2381.
30. Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, et al. (2013) TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma. Science Translational Medicine 5: 196ra98-196ra98. doi:10.1126/scitranslmed.3005753.
31. Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, et al. (2011) Genetic and Functional Studies Implicate HIF1 as a 14q Kidney Cancer Suppressor Gene. Cancer Discovery 1: 222-235. doi:10.1158/2159-8290.CD-11-0098.
32. Xu C-X, Zhao L, Yue P, Fang G, Tao H, et al. (2011) Augmentation of NVPBEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther 12: 549-555. doi:10.4161/cbt.12.6.16397.
33. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, et al. (2010) The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma. Clinical Cancer Research: 1-11. doi:10.1158/1078-0432.CCR-09-3022.
34. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, et al. (2009) Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin. Cancer Res 69: 6232-6240. doi:10.1158/0008-5472.CAN-09-0299.
35. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, et al. (2010) AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity. Cancer Res 70: 288-298. doi:10.1158/0008-5472.CAN-09-1751.
36. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38. doi:10.1371/journal.pbio.1000038.
37. Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends in Biochemical Sciences 36: 320-328. doi:10.1016/j.tibs.2011.03.006.
38. Dalby KN, Morrice N, Caudwell FB, Avruch J, Cohen P (1998) Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-1a/p90rsk that are inducible by MAPK. J Biol Chem 273: 1496-1505. (Pubitemid 28133672)
39. Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA, et al. (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499: 43-49. doi:10.1038/nature12222.
40. Migliardi G, Migliardi G, Sassi F, Sassi F, Torti D, et al. (2012) Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas. Clinical Cancer Research 18: 2515-2525. doi:10.1158/1078-0432.CCR-11-2683.
41. Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR (2012) The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer 106: 1386-1394. doi:10.1038/bjc.2012.70.
42. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356. doi:10.1038/nm.1890.
43. Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, et al. (2012) Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer. Cell 149: 307-321. doi:10.1016/j.cell.2012.02. 053.
44. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, et al. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540. (Pubitemid 29368255)
45. Maxwell PH (1999) The Tumour Suppressor Protein VHL Targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature: 1-5.
46. Krieg M, Haas R, Brauch H, Plate K (2000) Up-Regulation of hypoxia-inducible factors HIF1/2 under normoxic conditions in renal carcinoma cells by VHL suppressor gene loss of function: 1-9.